Meeting program

Thursday, April 18

*All times are in EET.

16:00 - 19:00 EET Satellite symposia

  • Novartis
  • Hoffman-La Roche
  • Takeda

Various satellite symposia will take place the day before the meeting for national and regional participants.


Friday, April 19

*All times are in EET.

08:45 - 09:00 EET Opening remarks

  • A Ivanaj (Albania), A Cili (Albania), D Coriu (Romania), K Döhner (Germany) & M Guenova (Bulgaria)

09:00 - 10:30 EET Session 1: Acute myeloid leukemia - The role of BMT

Chair: I Micheva (Bulgaria)

  • State-of-the-Art lecture: Why BMT for AML in 2024?
    J Esteve (Spain)
  • Juvenile myelomonocytic leukemia (JMML) with familial neurofibromatosis type 1 (NF1) and Stem Cell transplantation
  • G Rodica (Moldova)
  • Allogeneic hematopoietic stem cell transplant in AML patients in North Macedonia - Single center experience
    L Chadievski (North Macedonia)
  • The role of salvage therapy before allo-HSCT in R/R AML
    E Tekgündüz (Türkiye)
  • Allogeneic stem cell transplant in TP53-mutated acute myeloid leukemia
    M Stamouli (Greece)
  • Panel discussion
    All speakers

10:30 - 10:45 EET Coffee break

10:45 - 12:15 EET Session 2: The role of ASCT in the management of patients with multiple myeloma in 2024

Chairs: E Grouzi (Greece) & D Coriu (Romania)

  • State-of-the-Art lecture: The role of BMT in treatment of multiple myeloma in 2024
    D Coriu (Romania)
  • Is there rationale for the salvage ASCT in the era of new treatment modalities for multiple myeloma
    J Bila (Serbia)
  • BMT vs CAR-T cell therapy in R/R multiple myeloma patients
    A Cili (Albania)
  • Therapy with bispecific antibodies in patients with multiple myeloma: Romanian experience
    S Badelita (Romania)
  • Autologous transplantation for multiple myeloma in the era of new drugs
    I Mandac-Smoljanović (Croatia) - Virtual
  • Panel discussion
    All speakers

12:15 - 13:15 EET Lunch

13:15 - 14:45 EET Session 3: Acute lymphoblastic leukemia - Therapy & BMT

Chairs: S Unal Cangül (Türkiye) & S Buruiana (Moldova)

  • State-of-the-Art lecture: BMT in treatment of ALL in the era of immunotherapy and targeted therapy
    JM Ribera (Spain)
  • Early results of Carfilzomib/Melphalan (KMel) conditioning regimen in newly diagnosed patients with multiple myeloma fit for autologous stem cell transplantation
    Y Petriv (Bulgaria)
  • Significance of MRD on HSCT outcome in pediatric ALL patients
    O Tüfekçi (Türkiye)
  • Hematopoietic stem cell transplantation for acute leukemia - Single center activity from Bulgaria
    G Michaylov (Bulgaria)
  • Panel discussion
    All speakers

14:45 - 15:00 EET Coffee break

15:00 - 16:30 EET Session 4: Non-Hodgkin Lymphoma: Therapy for relapsed / refractory setting - Focused on new therapy and BMT

Chairs: E Kryeziu (Kosovo) & C Catan (Moldova)

  • State-of-the-Art lecture: The role of cellular therapy in the treatment of B cell lymphoma
    M Gomes da Silva (Portugal)
  • Hepatosplenic T-cell lymphoma a rare and aggressive disease
    A Ukimeraj (Kosovo)
  • Advances in the treatment of R/R mantle cell lymphomas
    E Birtaş (Türkiye)
  • New therapy in lymphoma
    OD Preda (Romania)
  • The relationship between experience and outcome in recently opened autologous transplant center in Split
    A Miljak (Croatia)
  • Panel discussion
    All speakers

16:30 - 18:00 EET Session 5: Hodgkin lymphoma: Therapy for relapsed / refractory setting - Focused on new therapy and BMT

Chairs: M Cem Ar (Türkiye) & S Krasniqi (Kosovo)

  • State-of-the-Art lecture: The role of BMT in treatment of Hodgkin Lymphoma
    I Aurer (Croatia)
  • Latest developments in new therapies for R/R Hodgkin lymphoma
    U Yılmaz (Türkiye)
  • Checkpoint inhibitors in relapsed/refractory classical Hodgkin lymphoma: Update on current and upcoming applications
    T Vassilakopoulos (Greece)
  • Current data on treatment of relapsed and refractory HL in North Macedonia
    A Pivkova Veljanovska (North Macedonia)
  • Hodgkin lymphoma: Treatment and challenges
    F Gashi (Kosovo)
  • Panel discussion
    All speakers

18:00 - 18:30 Closing remarks

  • A Ivanaj (Albania), A Cili (Albania), D Coriu (Romania), K Döhner (Germany) & M Guenova (Bulgaria)